LPTX Share Price | Leap Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Leap Therapeutics, Inc.?

Market Cap: As of Jun 18, Leap Therapeutics, Inc. has a market capitalization of 15.61 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Leap Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -69.18 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 35.05 million and total assets of 49.12 million.

Q: What does Leap Therapeutics, Inc. do?

Overview: Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies to treat cancer by inhibiting tumor-promoting pathways and activating the immune system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025). Market cap: USD 15.61 Million (Micro Cap).Key Metrics: P/E: NA (Loss Making), Industry P/E: NA, Dividend Yield: 0.00%, Debt Equity: -1.54, Return on Equity: -331.91%, Price to Book: 0.75.Contact Details: Address: 47 Thorndike St Ste B1-1, CAMBRIDGE MA: 02141-1799. Tel: 1 617 2524343. Website: https://www.leaptx.com/.

Q: Is Leap Therapeutics, Inc. overvalued or undervalued?

As of 12 August 2022, Leap Therapeutics, Inc. moved from a grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.78, an EV to EBIT of 0.22, and an astonishing ROCE of 626.53%, although the ROE is notably negative at -331.91%.In comparison to its peers, Leap Therapeutics, Inc. has a less favorable valuation with a peer EV to EBITDA of 0.2332, while companies like Precision BioSciences, Inc. show a more negative EV to EBITDA of -0.1189. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -89.25% compared to the index's 2.44%. Overall, the current valuation suggests that Leap Therapeutics, Inc. is overvalued in the market.

Q: Is Leap Therapeutics, Inc. technically bullish or bearish?

As of 28 July 2025, the technical trend for Leap Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal on the monthly. Moving averages indicate a mildly bearish stance on the daily timeframe. Bollinger Bands and OBV are also mildly bearish on the weekly, with no trend on the monthly for OBV. In terms of performance, the stock has seen a significant decline year-to-date of -88.82%, compared to a positive return of 12.22% for the S&P 500. Over the past year, the stock is down -88.84%, while the S&P 500 has gained 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the Bollinger Bands.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

649.86 k

Shareholding (Sep 2025)

FII

3.81%

Held by 15 FIIs

DII

71.22%

Held by 9 DIIs

Promoter

18.73%

How big is Leap Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Leap Therapeutics, Inc. has a market capitalization of 15.61 million, with net sales of 0.00 million and a net profit of -69.18 million over the last four quarters. The company reported shareholder's funds of 35.05 million and total assets of 49.12 million as of Dec 24.

View full answer

What does Leap Therapeutics, Inc. do?

22-Jun-2025

Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies that inhibit tumor-promoting pathways and activate the immune system. It operates as a micro-cap company with a market cap of $15.61 million and reported a net profit loss of $15 million as of March 2025.

View full answer

Who are in the management team of Leap Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Leap Therapeutics, Inc. includes Dr. Christopher Mirabelli (Chairman), Mr. Douglas Onsi (CEO), and several independent directors: Dr. Thomas Dietz, Dr. Monica Bertagnolli, Dr. James Cavanaugh, Dr. William Li, and Dr. Joseph Loscalzo. This team oversees the company's governance and strategic direction.

View full answer

Is Leap Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

Leap Therapeutics, Inc. is currently considered overvalued due to unfavorable financial metrics and peer comparisons, with a year-to-date return of -89.25% compared to the S&P 500's 2.44%.

View full answer

Is Leap Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 28, 2025, Leap Therapeutics, Inc. shows a mildly bearish trend, with significant year-to-date declines of -88.82% compared to a 12.22% gain in the S&P 500, influenced by daily moving averages and Bollinger Bands.

View full answer

Compare Leap Therapeutics, Inc. with Similar Stocks

Molecular Templates, Inc.eFFECTOR Therapeutics, Inc.SAB Biotherapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 52 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.58

Return on Equity

-1,717.44%

Price to Book

19.24

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

44.87%

6 Months

-80.74%

1 Year

-73.42%

2 Years

-90.1%

3 Years

-94.31%

4 Years

-96.52%

5 Years

-97.52%

Leap Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-24.21%

EBIT Growth (5y)

-158.78%

EBIT to Interest (avg)

-56.95

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.54

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

61.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.78

EV to EBIT

0.22

EV to EBITDA

0.22

EV to Capital Employed

1.40

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

626.53%

ROE (Latest)

-331.91%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 7 Schemes (6.23%)

Foreign Institutions

Held by 15 Foreign Institutions (3.81%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.41% vs -50.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.40",
          "val2": "-21.30",
          "chgp": "41.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.60",
          "val2": "-20.10",
          "chgp": "17.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.95% vs -49.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.10",
          "val2": "-86.60",
          "chgp": "19.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-67.60",
          "val2": "-81.40",
          "chgp": "16.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-12.40

-21.30

41.78%

Interest

0.00

Exceptional Items

-4.50

0.00

Consolidate Net Profit

-16.60

-20.10

17.41%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.41% vs -50.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-70.10

-86.60

19.05%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-67.60

-81.40

16.95%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.95% vs -49.08% in Dec 2023

All Annual Results

Company CV

About Leap Therapeutics, Inc.

Leap Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.

Company Coordinates

Company Details

47 Thorndike St Ste B1-1 , CAMBRIDGE MA : 02141-1799

Tel: 1 617 2524343

https://www.leaptx.com/

Registrar Details

Leap Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Leap Therapeutics, Inc.?

Watch in Real-Time

What does Leap Therapeutics, Inc. do?

Who are in the management team of Leap Therapeutics, Inc.?

Is Leap Therapeutics, Inc. overvalued or undervalued?

Is Leap Therapeutics, Inc. technically bullish or bearish?

Compare Leap Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Leap Therapeutics, Inc.

Company Coordinates